Diabetes drug affects neurodegeneration, PD via immunity

Published in BioWorld<br />By Anette Breindl <br />Senior Science Editor <br /><br />Thursday, June 28, 2018<br />Scientists at the Johns Hopkins Medical School have demonstrated that the experimental glucagon-like peptide 1 (GLP-1) receptor agonist NLY-01 (Neuraly Inc.) was protective against Parkinson's disease (PD) in two separate mouse models.<br />Buy Reprint

Published in BioWorld

By Anette Breindl 
Senior Science Editor 
 

Thursday, June 28, 2018

Scientists at the Johns Hopkins Medical School have demonstrated that the experimental glucagon-like peptide 1 (GLP-1) receptor agonist NLY-01 (Neuraly Inc.) was protective against Parkinson's disease (PD) in two separate mouse models.

Buy Reprint

 

Source: www.bioworld.com